BOLT

Bolt Biotherapeutics Inc. Common Stock (BOLT)

Stock · NASDAQ · Health Care

$4as of 10/16/2026

Price chart

Open in TradingView

Active signals

Support Confirmation23.2%200 SMA Touch0.0%
Support level
$3.81
Industry
Biotechnology: Pharmaceutical Preparations

BOLT Signal Track Record

How signals performed across all stocks →

What BOLT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Bollinger Band Breakout24-10.1%29%
Volume Spike22+2.8%59%
Bollinger Band Breakdown21-2.1%33%
200-Day Moving Average TouchActive now8-5.9%38%
Any 20-session window (baseline)-4.3%35%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
23

Fundamentals

1-day range
$3.96$4.48
Market cap
$7.44M
P/E (trailing)
—
P/E (forward)
-0.20
EPS (trailing)
$-16.44
Dividend yield
—
Beta
0.97
Avg. volume
27.3K
52-week range
$3.1$7.2
Next earnings: August 14, 2025 · EPS estimate $-6.27confirmed

How Bolt Biotherapeutics Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$7.70MR&D$28.53M (371%)SG&A$13.79M (179%)BOLT

Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub

Operating Income-$36.11M(-469%)

Forecasts

3 analyst ratings

Buy 70%
Hold 30%
Sell 0%
1-year price forecast
High
$75
+1775.0%
Median
$7
+75.0%
Low
$5
+25.0%

Bolt Biotherapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • BOLT
    Bolt Biotherapeutics Inc. Common Stock
    $4
    ▼ 5.66%
    Market cap $7.44MP/E —
    $3.1$7.2
  • MTVA
    MetaVia Inc. Common Stock
    $1.26
    ▼ 8.03%
    Market cap $7.49MP/E —
    $0.9661$14.85
  • MBRX
    Moleculin Biotech Inc. Common Stock
    $0.28
    ▼ 24.32%
    Market cap $7.50MP/E —
    $0.1614$15.75
  • ADXN
    Addex Therapeutics Ltd American Depositary Shares
    $2.76
    ▼ 8.61%
    Market cap $7.34MP/E —
    $0.018$0.069
  • APUS
    Apimeds Pharmaceuticals US Inc. Common Stock
    $4.04
    ▼ 7.97%
    Market cap $7.29MP/E —
    $1.51$403.1
  • CANF
    Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) Ordinary Shares
    $1.76
    ▼ 4.86%
    Market cap $7.63MP/E —
    $299$9,000,000
  • CNSP
    CNS Pharmaceuticals Inc. Common Stock
    $4.85
    ▼ 6.30%
    Market cap $7.65MP/E —
    $1.9$10.54

P/E shows — for peers not currently carrying a live signal of their own.

Insider Activity

Insider Actions →
Acquired
25.5K
Disposed
38.6K

Institutional Ownership

March 31, 2026

Total shares held
610.1K
Total value held
$2.48M
Institutional holders
21
Top holders this quarter
  • Unknown137.7K
  • Unknown77.2K
  • Unknown72.4K
  • Unknown42.6K
  • Unknown38.0K
  • Unknown36.0K
  • Unknown31.3K
  • Unknown30.8K
  • Unknown29.3K
  • Unknown28.8K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.